



# Corporate Overview

January 2025

spybiotech

Building the next  
generation of vaccines

# Two VLP candidates aimed at multi-billion-dollar markets

SpyTag/SpyCatcher proprietary protein superglue tools: unique, agile, specific, unbreakable

## CMV-SPYVLP01:

Phase 1 trial results positive,  
potential \$2B+ peak revenues  
based on best-in-class profile vs.  
Moderna candidate

## EBV-SPYVLP (Preclinical):

Oxford collaboration; targeting  
infectious mononucleosis and  
multiple sclerosis

## VLP and Adeno Platforms:

**Plug-and-display**  
modular system works with  
these and other platforms

**Fine-tuning of antigen  
density, mosaic  
co-display** optimizes  
immune response, provides  
breadth of coverage

**Universal targeting:**  
applicable to viral, bacterial,  
parasitic diseases, potentially  
cancer and allergies

## VLP Advantages

Validated Platform: Proven  
to be safe and effective as  
vaccines

Good stability profile

Longevity of immune  
response

Rapid manufacturing  
scalability of HBsAg-  
SpyCatcher VLP in yeast

## Adeno Advantages

Better antibody response  
than traditional Adeno  
vectors

T cells comparable to  
traditional Adeno vectors

Shielding of vector to avoid  
pre-existing antibodies

Mucosal delivery possible


## Extensive IP estate

With exclusive rights for all  
human and veterinary  
vaccinology



# Core technology and vaccine delivery platforms

**Extensive IP estate**  
with exclusive rights for  
human and veterinary  
vaccinology




## Advantages

- Covalent bond – strong
- Fast – rapid response
- Modular process – Plug and display
- Manufacturing advantage – solves technical hurdle
- No limitations on antigen size and complexity

## IP


- Multiple catcher/tag pairs (Spy, Spy003, Snoop, Dog)
- Exclusive for vaccines (non-exclusive for malaria)
- Therapeutic and Prophylactic vaccines
- **Exclusive license for all therapeutics (Adenovirus)**



## SPYVLP platform (Hepatitis B surface antigen )\*

### Advantages

- Better antibody response
- Better functional/neutralization activity
- Longevity of immune response
- Increased breadth (Pan Betacoronavirus)
- Potential to be transmission blocking



## SPYVECTOR platform (Adenovirus)\*

### Advantages

- Better antibody response than traditional Adeno vectors, better neutralization activity and increased breath
- T cells comparable to traditional Adeno vectors
- Shielding of vector to avoid pre-existing antibodies leads to better homologous boosting
- Mucosal delivery possible

# SPYVAC01 Phase 1 Trial Overview



## Dosing Schedule



Each Group is subdivided into seropositive (n=10) and seronegative (n=10)

## Objectives

- To assess the safety, immunogenicity and reactogenicity of SPYVLP01 with and without adjuvants in seropositive and seronegative healthy male and female volunteers

## Primary Endpoints

- Safety Profile and Reactogenicity profile
- Occurrence of solicited local and systemic reactogenicity signs and symptoms
- Occurrence of AEs and SAEs
- Changes in lab parameters

## Secondary Endpoints

- Pentamer specific binding antibodies and neutralizing antibodies

# Phase 1 results competitive with Moderna Phase 1 data

- **Safety:**

- All vaccine administrations have been completed
- No vaccine-related serious adverse events (SAEs) reported
- Tenderness and pain were the most common local reactions, were mild to moderate and self-resolving
- Overall profile is supportive of further Phase 2 development

- **Immunogenicity:**

- Significant neutralizing antibody response (epithelial cells) in CMV seropositive (all groups)
- Significant neutralising antibody response (epithelial cells) in CMV seronegative (adjuvanted groups)
- Fold increase competitive with Moderna's candidate currently in Phase 3 trials
- Good correlation between pentamer specific binding antibodies and neutralisation data

# SpyVLP01 peak revenues estimated at \$2.5B worldwide

Base case  
positioning using  
Gardasil and KOL  
feedback

Gardasil achieved  
\$5.3B in WW sales  
(2021)

Projected to reach  
\$10B by 2026

Pricing based on  
initial analyst  
estimates for  
Moderna CMV  
vaccine

Parity to Gardasil  
\$275/pt/dose US,  
\$200/pt/dose EU  
+UK

Target population  
(WOCBP)  
33.4mm in U.S.  
32.8mm in EU4  
and UK

SPYVLP01  
CMV



SpyVLP01 peak  
revenues  
estimated at  
\$2.5B, 40% share  
vs. Moderna





Thank you

spybiotech

Building the next  
generation of vaccines